Literature DB >> 18489636

Efficacy of neurotropin in fibromyalgia: a case report.

Katsuhiro Toda1, Yoshiko Tobimatsu.   

Abstract

Fibromyalgia is a refractory disorder that often necessitates long-term treatment. A 45-year-old woman has suffered from a stiff neck for 27 years and severe widespread pain for 4 years. Her visual analog scale (VAS), global-VAS, self-rating depression scale (SDS), and face scale were 48, 38, 42, and 15, respectively. She met the American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Four tablets of Neurotropin (NT) per day alone were administered, and her pain was gradually alleviated over 3 weeks. Her heavy sensation of the body and morning stiffness had almost disappeared 5 months later. Her VAS was 40 after 6 months, but the subjective pain decreased to half that at the initial visit. Her global-VAS, SDS, and face scale were 0, 35, and 8, respectively. No adverse effects were observed. NT, a nonprotein extract from the inflamed skin of rabbits inoculated with vaccinia virus, is a commonly prescribed analgesic drug for chronic pain in Japan. One of the advantages of NT is its few and slight adverse effects. Because NT does not suppress the synthesis of prostaglandin, NT does not cause digestive ulcers. Recent studies suggest that the analgesic mechanism of NT is due to the activation of a descending pain inhibitory system in the brain. Two open studies have shown the efficacy of NT for fibromyalgia. In order to determine whether NT is effective for fibromyalgia, a rigid clinical study, such as a double-blinded, placebo-controlled study, is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489636     DOI: 10.1111/j.1526-4637.2007.00279.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  4 in total

1.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

2.  A fibromyalgia patient with traumatic cerebrospinal fluid leak: a case report.

Authors:  K Toda; E Moriyama; S Ishikawa
Journal:  Clin Rheumatol       Date:  2008-05-24       Impact factor: 2.980

3.  Neurotropin alleviates rat osteocarcinoma pain via P2X3 receptor activation in the midbrain periaqueductal gray.

Authors:  Xingfeng Liu; Jingxin He; Zhi Xiao
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

4.  Upregulation of glycosaminoglycan synthesis by Neurotropin in nucleus pulposus cells via stimulation of chondroitin sulfate N-acetylgalactosaminyltransferase 1: A new approach to attenuation of intervertebral disc degeneration.

Authors:  Daisuke Sakai; Tomoko Nakai; Shunsuke Hiraishi; Yoshihiko Nakamura; Kiyoshi Ando; Mitsuru Naiki; Masahiko Watanabe
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.